{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:52:27Z","timestamp":1791064347002,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic further emphasized the global demand for heparin and its expanding clinical relevance, indicating that even one of the oldest drugs in medicine continues to reveal new therapeutic horizons. Traditionally recognized for its anticoagulant and antithrombotic activities, heparin is increasingly being explored for its versatile therapeutic potential in the treatment of a range of pulmonary diseases, including respiratory infections (e.g. COVID-19), Acute Respiratory Distress Syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. In all of these diseases, inhaled unfractionated heparin (UFH) therapy has been investigated in a number of clinical trials that have demonstrated promise for this drug when administered directly to the lungs. However, using heparin by this \u201coff label\u201d route of administration, poses a number of technical challenges: the physicochemical properties of heparin at therapeutic doses often results in highly viscous formulations, causing device blockage and drug sorption during nebulization. These limitations underscore the need for innovative formulation strategies to improve aerosol flow, reduce dosing inefficiencies, and enable reliable pulmonary administration. Advancing heparin formulations for delivery to the lung could therefore unlock significant benefits for a wide spectrum of respiratory disorders, marking a new chapter in the long medical history of this drug as discussed below.<\/jats:p>","DOI":"10.1007\/s00408-026-00905-y","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:27:20Z","timestamp":1782923240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies"],"prefix":"10.1007","volume":"204","author":[{"given":"Margarida","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M. P.","family":"van Haren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","volume":"75","author":"J Hogwood","year":"2023","unstructured":"Hogwood J, Mulloy B, Lever R et al (2023) Pharmacology of heparin and related drugs: an update. Pharmacol Rev 75:328\u2013379. https:\/\/doi.org\/10.1124\/pharmrev.122.000684","journal-title":"Pharmacol Rev"},{"key":"905_CR2","first-page":"1","volume-title":"Handbook of Experimental Pharmacology","author":"J Hogwood","year":"2025","unstructured":"Hogwood J, Gray E (2025) Heparin: over 100 years of anticoagulation. Handbook of Experimental Pharmacology. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 1\u201323"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","volume":"68","author":"B Mulloy","year":"2016","unstructured":"Mulloy B, Hogwood J, Gray E et al (2016) Pharmacology of heparin and related drugs. Pharmacol Rev 68:76\u2013141","journal-title":"Pharmacol Rev"},{"key":"905_CR4","doi-asserted-by":"crossref","unstructured":"Hogwood J, Gray E, Mulloy B (2023) Heparin, Heparan Sulphate and Sepsis : Potential New Options for Treatment. 1\u201318","DOI":"10.3390\/ph16020271"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"119818","DOI":"10.1016\/j.carbpol.2022.119818","volume":"295","author":"P Wang","year":"2022","unstructured":"Wang P, Chi L, Zhang Z et al (2022) Heparin: an old drug for new clinical applications. Carbohydr Polym 295:119818. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119818","journal-title":"Carbohydr Polym"},{"key":"905_CR6","doi-asserted-by":"publisher","first-page":"C1184","DOI":"10.1152\/ajpcell.00269.2013","volume":"306","author":"R Lever","year":"2014","unstructured":"Lever R, Rose MJ, McKenzie EA, Page CP (2014) Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium. Am J Physiol Physiol 306:C1184\u2013C1190. https:\/\/doi.org\/10.1152\/ajpcell.00269.2013","journal-title":"Am J Physiol Physiol"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejphar.2009.12.015","volume":"630","author":"R Lever","year":"2010","unstructured":"Lever R, Smailbegovic A, Page CP (2010) Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol 630:137\u2013144. https:\/\/doi.org\/10.1016\/j.ejphar.2009.12.015","journal-title":"Eur J Pharmacol"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"e0233644","DOI":"10.1371\/journal.pone.0233644","volume":"15","author":"J Hogwood","year":"2020","unstructured":"Hogwood J, Pitchford S, Mulloy B et al (2020) Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE 15:e0233644. https:\/\/doi.org\/10.1371\/journal.pone.0233644","journal-title":"PLoS ONE"},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1152\/jappl.1994.76.2.893","volume":"76","author":"T Ahmed","year":"1994","unstructured":"Ahmed T, Syriste T, Mendelssohn R et al (1994) Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation? J Appl Physiol 76:893\u2013901. https:\/\/doi.org\/10.1152\/jappl.1994.76.2.893","journal-title":"J Appl Physiol"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3389\/fphar.2020.01011","volume":"11","author":"JA Voynow","year":"2020","unstructured":"Voynow JA, Zheng S, Kummarapurugu AB (2020) Glycosaminoglycans as multifunctional anti-elastase and anti-inflammatory drugs in cystic fibrosis lung disease. Front Pharmacol 11:1011","journal-title":"Front Pharmacol"},{"key":"905_CR11","doi-asserted-by":"publisher","unstructured":"Shute JK (2023) Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals 16. https:\/\/doi.org\/10.3390\/ph16040584","DOI":"10.3390\/ph16040584"},{"key":"905_CR12","doi-asserted-by":"publisher","unstructured":"Van Haren FMP, Loon LM, Van, Steins A et al (2022) Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. 2802\u20132813. https:\/\/doi.org\/10.1111\/bcp.15212","DOI":"10.1111\/bcp.15212"},{"key":"905_CR13","doi-asserted-by":"publisher","first-page":"103339","DOI":"10.1016\/j.eclinm.2025.103339","volume":"88","author":"FMP van Haren","year":"2025","unstructured":"van Haren FMP, Valle SJ, Neto S et al (2025) Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial. eClinicalMedicine 88:103339. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103339","journal-title":"eClinicalMedicine"},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"13326","DOI":"10.1038\/s41598-023-40489-8","volume":"13","author":"R Ashmawy","year":"2023","unstructured":"Ashmawy R, Zaki A, Baess A, El Sayed I (2023) Efficacy and safety of inhaled heparin in asthmatic and chronic obstructive pulmonary disease patients: a systematic review and a meta-analysis. Sci Rep 13:13326. https:\/\/doi.org\/10.1038\/s41598-023-40489-8","journal-title":"Sci Rep"},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jconrel.2012.07.008","volume":"162","author":"A Yildiz","year":"2012","unstructured":"Yildiz A, John E, \u00d6zsoy Y et al (2012) Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation. J Control Release 162:456\u2013463. https:\/\/doi.org\/10.1016\/j.jconrel.2012.07.008","journal-title":"J Control Release"},{"key":"905_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pupt.2016.11.002","volume":"41","author":"R Lever","year":"2016","unstructured":"Lever R, Smailbegovic A, Riffo-Vasquez Y et al (2016) Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin. Pulm Pharmacol Ther 41:96\u2013102. https:\/\/doi.org\/10.1016\/j.pupt.2016.11.002","journal-title":"Pulm Pharmacol Ther"},{"key":"905_CR17","doi-asserted-by":"publisher","unstructured":"Kjell\u00e9n L, Lindahl U (2024) Heparin and heparan sulfate \u2014 The essence of sequence. 1\u20138. https:\/\/doi.org\/10.1002\/pgr2.70006","DOI":"10.1002\/pgr2.70006"},{"key":"905_CR18","first-page":"201","volume-title":"The Endothelial Glycocalyx in Health and Human Disease BT - Handbook of Microcirculation","author":"K Oshima","year":"2025","unstructured":"Oshima K, Schmidt EP (2025) In: Tuma RF, Breslin JW, Peirce-Cottler S, Murfee WL (eds) The Endothelial Glycocalyx in Health and Human Disease BT - Handbook of Microcirculation. Springer Nature Switzerland, Cham, pp 201\u2013245"},{"key":"905_CR19","doi-asserted-by":"publisher","unstructured":"Page C (2013) Heparin and Related Drugs: Beyond Anticoagulant Activity. ISRN Pharmacol 2013:1\u201313. https:\/\/doi.org\/10.1155\/2013\/910743","DOI":"10.1155\/2013\/910743"},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pupt.2013.12.001","volume":"28","author":"T Ahmed","year":"2014","unstructured":"Ahmed T, Smith G, Abraham WM (2014) Heparin-derived supersulfated disaccharide inhibits allergic airway responses in sheep. Pulm Pharmacol Ther 28:77\u201386. https:\/\/doi.org\/10.1016\/j.pupt.2013.12.001","journal-title":"Pulm Pharmacol Ther"},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coph.2018.01.006","volume":"40","author":"JK Shute","year":"2018","unstructured":"Shute JK, Puxeddu E, Calzetta L (2018) Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD. Curr Opin Pharmacol 40:39\u201345. https:\/\/doi.org\/10.1016\/j.coph.2018.01.006","journal-title":"Curr Opin Pharmacol"},{"key":"905_CR22","doi-asserted-by":"publisher","unstructured":"Al-Hakim A (2021) General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market. Clin Appl Thromb 27. https:\/\/doi.org\/10.1177\/10760296211052293","DOI":"10.1177\/10760296211052293"},{"key":"905_CR23","unstructured":"USP (2010) Heparin Contamination. https:\/\/www.usp.org\/sites\/default\/files\/fda-exhibit\/topics\/contamination.html. Accessed 26 Jan 2026"},{"key":"905_CR24","doi-asserted-by":"publisher","unstructured":"Olson G, Jeske W, Iqbal O et al (2023) Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin. Clin Appl Thromb 29. https:\/\/doi.org\/10.1177\/10760296231163251","DOI":"10.1177\/10760296231163251"},{"key":"905_CR25","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2352-3026(22)00171-5","volume":"9","author":"BE Fan","year":"2022","unstructured":"Fan BE, Favaloro EJ (2022) Counting the carbon cost of heparin: an evolving tragedy of the commons? Lancet Haematol 9:e469\u2013e471. https:\/\/doi.org\/10.1016\/S2352-3026(22)00171-5","journal-title":"Lancet Haematol"},{"key":"905_CR26","unstructured":"US-FDA (2025) FDA Encourages Reintroduction of Bovine-Sourced Heparin | FDA. https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/fda-encourages-reintroduction-bovine-sourced-heparin. Accessed 24 Oct 2025"},{"key":"905_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1164\/rccm.202207-1407ED","volume":"206","author":"DMG Halpin","year":"2022","unstructured":"Halpin DMG, Vogelmeier CF, Agusti A (2022) Lung health for all: chronic obstructive lung disease and world lung day 2022. Am J Respir Crit Care Med 206:669\u2013671","journal-title":"Am J Respir Crit Care Med"},{"key":"905_CR28","unstructured":"ONS (2023) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/30march2023. Accessed 22 Feb 2026"},{"key":"905_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/thoraxjnl-2021-218459","volume":"77","author":"I Hall","year":"2022","unstructured":"Hall I, Walker S, Holgate ST (2022) Respiratory research in the UK: investing for the next 10 years. Thorax 77:851\u2013853","journal-title":"Thorax"},{"key":"905_CR30","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442","journal-title":"PLoS Med"},{"key":"905_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/tc-2024-059219","author":"S Golder","year":"2025","unstructured":"Golder S, Hartwell G, Barnett LM et al (2025) Vaping and harm in young people: umbrella review. Tob Control. https:\/\/doi.org\/10.1136\/tc-2024-059219","journal-title":"Tob Control"},{"key":"905_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","volume":"41","author":"I Capila","year":"2002","unstructured":"Capila I, Linhardt RJ (2002) Heparin\u2013protein interactions. Angew Chemie Int Ed 41:390\u2013412","journal-title":"Angew Chemie Int Ed"},{"key":"905_CR33","doi-asserted-by":"crossref","unstructured":"Lever R, Mulloy B, Page CP (2012) Heparin-a century of progress. Springer Science & Business Media","DOI":"10.1007\/978-3-642-23056-1"},{"key":"905_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.carres.2014.06.023","volume":"403","author":"B Casu","year":"2015","unstructured":"Casu B, Naggi A, Torri G (2015) Re-visiting the structure of heparin. Carbohydr Res 403:60\u201368","journal-title":"Carbohydr Res"},{"key":"905_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.bjp.0707298","volume":"151","author":"R Lever","year":"2007","unstructured":"Lever R, Lo WT, Faraidoun M et al (2007) Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 151:837\u2013843","journal-title":"Br J Pharmacol"},{"key":"905_CR36","doi-asserted-by":"crossref","unstructured":"Mousavi S, Moradi M, Khorshidahmad T, Motamedi M (2015) Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Pharm Sci 2015:507151","DOI":"10.1155\/2015\/507151"},{"key":"905_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","volume":"24","author":"FMP van Haren","year":"2020","unstructured":"van Haren FMP, Page C, Laffey JG et al (2020) Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 24:454. https:\/\/doi.org\/10.1186\/s13054-020-03148-2","journal-title":"Crit Care"},{"key":"905_CR38","doi-asserted-by":"publisher","first-page":"19902","DOI":"10.1038\/s41598-024-70064-8","volume":"14","author":"VT Ramos da Silva Grillo","year":"2024","unstructured":"Ramos da Silva Grillo VT, Bertanha M, da Silva Rodrigues L et al (2024) Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I\/II randomized and triple-blind clinical trial. Sci Rep 14:19902. https:\/\/doi.org\/10.1038\/s41598-024-70064-8","journal-title":"Sci Rep"},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0310057X251322783","volume":"53","author":"RJ Smith","year":"2025","unstructured":"Smith RJ, Ghosh AN, Said S et al (2025) A randomised, open-label trial of nebulised unfractionated heparin in patients mechanically ventilated for COVID-19. Anaesth Intensive Care 53:238\u2013252. https:\/\/doi.org\/10.1177\/0310057X251322783","journal-title":"Anaesth Intensive Care"},{"key":"905_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40635-025-00727-x","volume":"13","author":"D Cosgrave","year":"2025","unstructured":"Cosgrave D, McNicholas B, Hanley C et al (2025) Can nebulised heparin reduce acute lung injury in patients with SARS\u2013CoV\u20132 requiring advanced respiratory support in Ireland: the CHARTER\u2013Ireland phase Ib\/IIa, randomised, parallel-group, open-label study. Intensive care Med Exp 13:15. https:\/\/doi.org\/10.1186\/s40635-025-00727-x","journal-title":"Intensive care Med Exp"},{"key":"905_CR41","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bph.15304","volume":"178","author":"JA Tree","year":"2021","unstructured":"Tree JA, Turnbull JE, Buttigieg KR et al (2021) Unfractionated heparin inhibits live wild type SARS-CoV\u20102 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol 178:626\u2013635","journal-title":"Br J Pharmacol"},{"key":"905_CR42","doi-asserted-by":"crossref","unstructured":"Mycroft-west C, Su D, Elli S et al (2020) The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. Methods & Materials, pp 1\u20139","DOI":"10.1101\/2020.02.29.971093"},{"key":"905_CR43","doi-asserted-by":"publisher","unstructured":"Rizzo AN, Haeger SM, Oshima K et al (2022) Alveolar epithelial glycocalyx degradation mediates surfactant dysfunction and contributes to acute respiratory distress syndrome. JCI insight 7. https:\/\/doi.org\/10.1172\/jci.insight.154573","DOI":"10.1172\/jci.insight.154573"},{"key":"905_CR44","doi-asserted-by":"publisher","first-page":"C799","DOI":"10.1152\/ajpcell.00555.2022","volume":"324","author":"AN Rizzo","year":"2023","unstructured":"Rizzo AN, Schmidt EP (2023) The role of the alveolar epithelial glycocalyx in acute respiratory distress syndrome. Am J Physiol Cell Physiol 324:C799\u2013C806. https:\/\/doi.org\/10.1152\/ajpcell.00555.2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"905_CR45","doi-asserted-by":"publisher","first-page":"111561","DOI":"10.1016\/j.biopha.2021.111561","volume":"139","author":"M Qiu","year":"2021","unstructured":"Qiu M, Huang S, Luo C et al (2021) Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed Pharmacother 139:111561. https:\/\/doi.org\/10.1016\/j.biopha.2021.111561","journal-title":"Biomed Pharmacother"},{"key":"905_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2020.00483","volume":"11","author":"H Crijns","year":"2020","unstructured":"Crijns H, Vanheule V, Proost P (2020) Targeting chemokine\u2014glycosaminoglycan interactions to inhibit inflammation. Front Immunol 11:483","journal-title":"Front Immunol"},{"key":"905_CR47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","volume":"9","author":"B Dixon","year":"2021","unstructured":"Dixon B, Smith RJ, Campbell DJ et al (2021) Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 9:360\u2013372. https:\/\/doi.org\/10.1016\/S2213-2600(20)30470-7","journal-title":"Lancet Respir Med"},{"key":"905_CR48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5005\/jp-journals-10071-24420","volume":"27","author":"B Gupta","year":"2023","unstructured":"Gupta B, Chandrakar S, Gupta N, Jain G (2023) Nebulized Heparin to Reduce COVID-19-induced Acute Lung Injury: A Prospective Observational Study. Indian J Crit Care Med 27:222\u2013224. https:\/\/doi.org\/10.5005\/jp-journals-10071-24420","journal-title":"Indian J Crit Care Med"},{"key":"905_CR49","doi-asserted-by":"publisher","first-page":"102212","DOI":"10.1016\/j.pupt.2023.102212","volume":"80","author":"G DeNucci","year":"2023","unstructured":"DeNucci G, Wilkinson T, Sverdloff C et al (2023) Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study. Pulm Pharmacol Ther 80:102212","journal-title":"Pulm Pharmacol Ther"},{"key":"905_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd724","volume":"1","author":"R Lever","year":"2002","unstructured":"Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140\u2013148","journal-title":"Nat Rev Drug Discov"},{"key":"905_CR51","doi-asserted-by":"crossref","unstructured":"Tyrrell DJ, Horne AP, Holme KR et al (1999) Heparin in Inflammation: Potential Therapeutic Applications beyond Anticoagulation. In: August JT, Anders MW, Murad F, Coyle JTBT-A in P (eds). Academic Press, pp 151\u2013208","DOI":"10.1016\/S1054-3589(08)60471-8"},{"key":"905_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pupt.2006.04.004","volume":"19","author":"RA Brown","year":"2006","unstructured":"Brown RA, Allegra L, Matera MG et al (2006) Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19:419\u2013424. https:\/\/doi.org\/10.1016\/j.pupt.2006.04.004","journal-title":"Pulm Pharmacol Ther"},{"key":"905_CR53","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s10753-014-9812-6","volume":"37","author":"Z-G Luan","year":"2014","unstructured":"Luan Z-G, Naranpurev M, Ma X-C (2014) Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 37:924\u2013932. https:\/\/doi.org\/10.1007\/s10753-014-9812-6","journal-title":"Inflammation"},{"key":"905_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12931-017-0572-3","volume":"18","author":"M Camprub\u00ed\u2013Rimblas","year":"2017","unstructured":"Camprub\u00ed\u2013Rimblas M, Guillamat-Prats R, Lebouvier T et al (2017) Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury. Respir Res 18:89","journal-title":"Respir Res"},{"key":"905_CR55","doi-asserted-by":"publisher","first-page":"148054","DOI":"10.1016\/j.ijbiomac.2025.148054","volume":"330","author":"X Zeng","year":"2025","unstructured":"Zeng X, Hou Y, Luo L et al (2025) Multifaceted roles of heparin and its derivatives in inflammation and cancer: Mechanisms, clinical applications, and future directions. Int J Biol Macromol 330:148054. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148054","journal-title":"Int J Biol Macromol"},{"key":"905_CR56","doi-asserted-by":"crossref","unstructured":"Shute J, Calzetta L, Cardaci V et al (2016) A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD. In: European Respiratory Journal. p OA3311","DOI":"10.1183\/13993003.congress-2016.OA3311"},{"key":"905_CR57","doi-asserted-by":"publisher","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","volume":"293","author":"VJ Broughton-Head","year":"2007","unstructured":"Broughton-Head VJ, Shur J, Carroll MP et al (2007) Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 293:L1240\u2013L1249. https:\/\/doi.org\/10.1152\/ajplung.00206.2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"905_CR58","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4097\/kja.19418","volume":"73","author":"TM Ashoor","year":"2020","unstructured":"Ashoor TM, Hasseb AM, Esmat IM (2020) Nebulized heparin and salbutamol versus salbutamol alone in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation: a double-blind randomized controlled trial. Korean J Anesthesiol 73:509\u2013517. https:\/\/doi.org\/10.4097\/kja.19418","journal-title":"Korean J Anesthesiol"},{"key":"905_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pupt.2017.10.001","volume":"48","author":"JK Shute","year":"2018","unstructured":"Shute JK, Calzetta L, Cardaci V et al (2018) Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study. Pulm Pharmacol Ther 48:88\u201396","journal-title":"Pulm Pharmacol Ther"},{"key":"905_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0002-9149(64)90100-6","volume":"14","author":"JP Boyle","year":"1964","unstructured":"Boyle JP, Smart RH, Shirey JK (1964) Heparin in the Treatment of Chronic Obstructive Bronchopulmonary Disease. Am J Cardiol 14:25\u201328. https:\/\/doi.org\/10.1016\/0002-9149(64)90100-6","journal-title":"Am J Cardiol"},{"key":"905_CR61","doi-asserted-by":"publisher","unstructured":"Savin IA, Zenkova MA, Sen\u2019kova AV (2023) Bronchial Asthma, Airway Remodeling and Lung Fibrosis as Successive Steps of One Process. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms242216042","DOI":"10.3390\/ijms242216042"},{"key":"905_CR62","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1164\/arrd.1968.98.5.886","volume":"98","author":"NL Fine","year":"1968","unstructured":"Fine NL, Shim C, Williams MHJ (1968) Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis 98:886\u2013887. https:\/\/doi.org\/10.1164\/arrd.1968.98.5.886","journal-title":"Am Rev Respir Dis"},{"key":"905_CR63","first-page":"108","volume":"27","author":"EJJ Bardana","year":"1969","unstructured":"Bardana EJJ, Edwards MJ, Pirofsky B (1969) Heparin as treatment for bronchospasm of asthma. Ann Allergy 27:108\u2013113","journal-title":"Ann Allergy"},{"key":"905_CR64","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1164\/ajrccm.153.6.8665036","volume":"153","author":"Z Diamant","year":"1996","unstructured":"Diamant Z, Timmers MC, van der Veen H et al (1996) Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 153:1790\u20131795. https:\/\/doi.org\/10.1164\/ajrccm.153.6.8665036","journal-title":"Am J Respir Crit Care Med"},{"key":"905_CR65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1164\/ajrccm\/147.1.160","volume":"147","author":"SD Bowler","year":"1993","unstructured":"Bowler SD, Smith SM, Lavercombe PS (1993) Heparin Inhibits the Immediate Response to Antigen in the Skin and Lungs of Allergic Subjects. Am Rev Respir Dis 147:160\u2013163. https:\/\/doi.org\/10.1164\/ajrccm\/147.1.160","journal-title":"Am Rev Respir Dis"},{"key":"905_CR66","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJM199307083290204","volume":"329","author":"T Ahmed","year":"1993","unstructured":"Ahmed T, Garrigo J, Danta I (1993) Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 329:90\u201395. https:\/\/doi.org\/10.1056\/NEJM199307083290204","journal-title":"N Engl J Med"},{"key":"905_CR67","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1053\/rmed.1999.0677","volume":"94","author":"KE Bendstrup","year":"2000","unstructured":"Bendstrup KE, Jensen JI (2000) Inhaled heparin is effective in exacerbations of asthma. Respir Med 94:174\u2013175. https:\/\/doi.org\/10.1053\/rmed.1999.0677","journal-title":"Respir Med"},{"key":"905_CR68","doi-asserted-by":"publisher","unstructured":"Talbot T, Roe T, Dushianthan A (2024) Management of Acute Life-Threatening Asthma Exacerbations in the Intensive Care Unit. Appl Sci 14. https:\/\/doi.org\/10.3390\/app14020693","DOI":"10.3390\/app14020693"},{"key":"905_CR69","doi-asserted-by":"publisher","first-page":"104065","DOI":"10.1016\/j.drudis.2024.104065","volume":"29","author":"Z Liu","year":"2024","unstructured":"Liu Z, Ye Y, Ma Y et al (2024) Inhaled heparin: Past, present, and future. Drug Discov Today 29:104065. https:\/\/doi.org\/10.1016\/j.drudis.2024.104065","journal-title":"Drug Discov Today"},{"key":"905_CR70","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1172\/JCI60331","volume":"122","author":"MA Matthay","year":"2012","unstructured":"Matthay MA, Ware LB, Zimmerman GA (2012) The acute respiratory distress syndrome. J Clin Invest 122:2731\u20132740","journal-title":"J Clin Invest"},{"key":"905_CR71","first-page":"1009","volume":"2","author":"JN Gonzales","year":"2015","unstructured":"Gonzales JN, Lucas R, Verin AD (2015) The acute respiratory distress syndrome: mechanisms and perspective therapeutic approaches. Austin J Vasc Med 2:1009","journal-title":"Austin J Vasc Med"},{"key":"905_CR72","doi-asserted-by":"crossref","unstructured":"Ware LB (2006) Pathophysiology of acute lung injury and the acute respiratory distress syndrome. In: Seminars in respiratory and critical care medicine. Copyright\u00a9 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New \u2026 pp 337\u2013349","DOI":"10.1055\/s-2006-948288"},{"key":"905_CR73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/atm.2018.01.08","volume":"6","author":"M Camprub\u00ed-Rimblas","year":"2018","unstructured":"Camprub\u00ed-Rimblas M, Tantiny\u00e0 N, Bringu\u00e9 J et al (2018) Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl Med 6:36","journal-title":"Ann Transl Med"},{"key":"905_CR74","doi-asserted-by":"publisher","unstructured":"Rezoagli E, Fumagalli R, Bellani G (2017) Definition and epidemiology of acute respiratory distress syndrome. 5:1\u201312. https:\/\/doi.org\/10.21037\/atm.2017.06.62","DOI":"10.21037\/atm.2017.06.62"},{"key":"905_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jcrc.2018.12.006","volume":"50","author":"V Muthu","year":"2019","unstructured":"Muthu V, Agarwal R, Dhooria S et al (2019) Epidemiology, lung mechanics and outcomes of ARDS : A comparison between pregnant and non-pregnant subjects. J Crit Care 50:207\u2013212. https:\/\/doi.org\/10.1016\/j.jcrc.2018.12.006","journal-title":"J Crit Care"},{"key":"905_CR76","doi-asserted-by":"publisher","unstructured":"Xiao LX, Zhu DL, Chen J et al (2024) Exploring the therapeutic role of early heparin administration in ARDS management: a MIMIC \u2013 IV database analysis. J Intensive Care 1\u201314. https:\/\/doi.org\/10.1186\/s40560-024-00723-5","DOI":"10.1186\/s40560-024-00723-5"},{"key":"905_CR77","doi-asserted-by":"publisher","unstructured":"Zhou Y (2025) Association Between Heparin-Binding Protein and Extubation Outcomes in ARDS: A Retrospective Association Between Heparin-Binding Protein and Extubation Outcomes in ARDS : A Retrospective Cohort Study. 7074. https:\/\/doi.org\/10.2147\/IJGM.S559258","DOI":"10.2147\/IJGM.S559258"},{"key":"905_CR78","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1111\/bcp.15212","volume":"88","author":"FMP van Haren","year":"2022","unstructured":"van Haren FMP, van Loon LM, Steins A et al (2022) Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. Br J Clin Pharmacol 88:2802\u20132813. https:\/\/doi.org\/10.1111\/bcp.15212","journal-title":"Br J Clin Pharmacol"},{"key":"905_CR79","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jss.2019.01.020","volume":"238","author":"Y Liu","year":"2019","unstructured":"Liu Y, Mu S, Li X et al (2019) Unfractionated Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions. J Surg Res 238:175\u2013185. https:\/\/doi.org\/10.1016\/j.jss.2019.01.020","journal-title":"J Surg Res"},{"key":"905_CR80","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.thromres.2011.07.044","volume":"128","author":"R Ding","year":"2011","unstructured":"Ding R, Zhao D, Guo R et al (2011) Treatment with unfractionated heparin attenuates coagulation and in fl ammation in endotoxemic mice. Thromb Res 128:e160\u2013e165. https:\/\/doi.org\/10.1016\/j.thromres.2011.07.044","journal-title":"Thromb Res"},{"key":"905_CR81","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00134-008-1063-2","volume":"34","author":"F Ader","year":"2008","unstructured":"Ader F, Le Berre R, Fackeure R et al (2008) In vivo effect of adhesion inhibitor heparin on Legionella pneumophila pathogenesis in a murine pneumonia model. Intensive Care Med 34:1511\u20131519. https:\/\/doi.org\/10.1007\/s00134-008-1063-2","journal-title":"Intensive Care Med"},{"key":"905_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/jamp.2009.0779","volume":"23","author":"JJ Hofstra","year":"2010","unstructured":"Hofstra JJ, Vlaar AP, Cornet AD et al (2010) Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 23:105\u2013111. https:\/\/doi.org\/10.1089\/jamp.2009.0779","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"905_CR83","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/cc8040","volume":"13","author":"JJ Hofstra","year":"2009","unstructured":"Hofstra JJ, Cornet AD, de Rooy BF et al (2009) Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 13:R145. https:\/\/doi.org\/10.1186\/cc8040","journal-title":"Crit Care"},{"key":"905_CR84","doi-asserted-by":"crossref","unstructured":"Tuinman PR, Dixon B, Levi M et al (2012) Nebulized anticoagulants for acute lung injury -. a systematic review of preclinical and clinical investigations Anticoagulant pathways","DOI":"10.1186\/cc11325"},{"key":"905_CR85","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/00003246-200203000-00024","volume":"30","author":"O Tasaki","year":"2002","unstructured":"Tasaki O, Mozingo DW, Dubick MA et al (2002) Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Crit Care Med 30:637\u2013643. https:\/\/doi.org\/10.1097\/00003246-200203000-00024","journal-title":"Crit Care Med"},{"key":"905_CR86","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00004630-199805000-00004","volume":"19","author":"MH Desai","year":"1998","unstructured":"Desai MH, Mlcak R, Richardson J et al (1998) Reduction in Mortality in Pediatric Patients with Inhalation Injury with Aerosolized Heparin\/Acetylcystine Therapy. J Burn Care Rehabil 19:210\u2013212. https:\/\/doi.org\/10.1097\/00004630-199805000-00004","journal-title":"J Burn Care Rehabil"},{"key":"905_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/BCR.0b013e318198a268","volume":"30","author":"AC Miller","year":"2009","unstructured":"Miller AC, Rivero A, Ziad S et al (2009) Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 30:249\u2013256. https:\/\/doi.org\/10.1097\/BCR.0b013e318198a268","journal-title":"J Burn Care Res"},{"key":"905_CR88","doi-asserted-by":"publisher","first-page":"R180","DOI":"10.1186\/cc9286","volume":"14","author":"B Dixon","year":"2010","unstructured":"Dixon B, Schultz MJ, Smith R et al (2010) Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit care 14:R180","journal-title":"Crit care"},{"key":"905_CR89","doi-asserted-by":"publisher","first-page":"107518","DOI":"10.1016\/j.burns.2025.107518","volume":"51","author":"SM Hakim","year":"2025","unstructured":"Hakim SM, Fouad MN, Habib MK et al (2025) Effect of early administration of inhaled heparin on outcomes of smoke inhalation injury: A randomized controlled trial. Burns 51:107518. https:\/\/doi.org\/10.1016\/j.burns.2025.107518","journal-title":"Burns"},{"key":"905_CR90","doi-asserted-by":"publisher","unstructured":"Elsharnouby NM, Eid HEA, Elezz NFA, Aboelatta YA (2014) Heparin \/ N -acetylcysteine: An adjuvant in the management of burn inhalation injury \u2606 A study of different doses. J Crit Care 29. https:\/\/doi.org\/10.1016\/j.jcrc.2013.06.017. :182.e1-182.e4","DOI":"10.1016\/j.jcrc.2013.06.017"},{"key":"905_CR91","doi-asserted-by":"publisher","first-page":"e19906","DOI":"10.7759\/cureus.19906","volume":"13","author":"D Kocakaya","year":"2021","unstructured":"Kocakaya D, Olgun Y\u0131ld\u0131zeli S, Ataizi-\u00c7elikel \u00c7, Ceyhan B (2021) Prolonged Methylprednisolone Therapy in the Fibro-Proliferative Phase of Acute Respiratory Distress Syndrome. Cureus 13:e19906. https:\/\/doi.org\/10.7759\/cureus.19906","journal-title":"Cureus"},{"key":"905_CR92","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1183\/09031936.06.00069005","volume":"27","author":"DJ Serisier","year":"2006","unstructured":"Serisier DJ, Shute JK, Hockey PM et al (2006) Inhaled heparin in cystic fibrosis. Eur Respir J 27:354\u2013358. https:\/\/doi.org\/10.1183\/09031936.06.00069005","journal-title":"Eur Respir J"},{"key":"905_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1183\/09031936.01.17100360","volume":"17","author":"M Ledson","year":"2001","unstructured":"Ledson M, Gallagher M, Hart CA, Walshaw M (2001) Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur Respir J 17:36\u201338. https:\/\/doi.org\/10.1183\/09031936.01.17100360","journal-title":"Eur Respir J"},{"key":"905_CR94","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/ijms19010207","volume":"19","author":"NI Lor\u00e8","year":"2018","unstructured":"Lor\u00e8 NI, Veraldi N, Riva C et al (2018) Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection. Int J Mol Sci 19:207","journal-title":"Int J Mol Sci"},{"key":"905_CR95","doi-asserted-by":"publisher","unstructured":"Cagno V, Tseligka ED, Jones ST, Tapparel C (2019) Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses 11:. https:\/\/doi.org\/10.3390\/v11070596","DOI":"10.3390\/v11070596"},{"key":"905_CR96","doi-asserted-by":"publisher","unstructured":"Shur J, Nevell TG, Ewen RJ et al (2008) Cospray-Dried Unfractionated Heparin With L -Leucine as a Dry Powder Inhaler Mucolytic for Cystic Fibrosis Therapy. 97:4857\u20134868. https:\/\/doi.org\/10.1002\/jps","DOI":"10.1002\/jps"},{"key":"905_CR97","doi-asserted-by":"publisher","DOI":"10.1080\/03639040701657552","author":"J Shur","year":"2008","unstructured":"Shur J, Nevell TG, Shute JK et al (2008) The Spray Drying of Unfractionated Heparin: Optimization of the Operating Parameters The Spray Drying of Unfractionated Heparin : Optimization. 9045. https:\/\/doi.org\/10.1080\/03639040701657552","journal-title":"9045"},{"key":"905_CR98","doi-asserted-by":"publisher","unstructured":"Zhou-suckow Z, Duerr J, Hagner M et al (2017) Airway mucus, inflammation and remodeling : emerging links in the pathogenesis of chronic lung diseases. 537\u2013550. https:\/\/doi.org\/10.1007\/s00441-016-2562-z","DOI":"10.1007\/s00441-016-2562-z"},{"key":"905_CR99","doi-asserted-by":"publisher","unstructured":"Bal\u00e1zs A, Mall MA (2019) Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL - 1 signaling pathway. https:\/\/doi.org\/10.1002\/ppul.24462","DOI":"10.1002\/ppul.24462"},{"key":"905_CR100","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4103\/roaic.roaic_62_23","volume":"11","author":"TI Ismail","year":"2024","unstructured":"Ismail TI, Bader M, Mahrous RSS, Abulfatth AM (2024) The effect of nebulized heparin in the attenuation of coronavirus disease 2019-induced acute lung injury: a randomized controlled trial. Res Opin Anesth Intensive Care 11:92\u2013101. https:\/\/doi.org\/10.4103\/roaic.roaic_62_23","journal-title":"Res Opin Anesth Intensive Care"},{"key":"905_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc6947","volume":"12","author":"PM Suter","year":"2008","unstructured":"Suter PM (2008) Nebulised heparin: A new approach to the treatment of acute lung injury? Crit Care 12:1\u20132. https:\/\/doi.org\/10.1186\/cc6947","journal-title":"Crit Care"},{"key":"905_CR102","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/cc6894","volume":"12","author":"B Dixon","year":"2008","unstructured":"Dixon B, Santamaria JD, Campbell DJ (2008) A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 12:R64. https:\/\/doi.org\/10.1186\/cc6894","journal-title":"Crit Care"},{"key":"905_CR103","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/BCR.0000000000000439","volume":"38","author":"AM McIntire","year":"2017","unstructured":"McIntire AM, Harris SA, Whitten JA et al (2017) Outcomes Following the Use of Nebulized Heparin for Inhalation Injury (HIHI Study). J Burn care Res Off Publ Am Burn Assoc 38:45\u201352. https:\/\/doi.org\/10.1097\/BCR.0000000000000439","journal-title":"J Burn care Res Off Publ Am Burn Assoc"},{"key":"905_CR104","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.burns.2011.07.006","volume":"37","author":"LY Yip","year":"2011","unstructured":"Yip LY, Lim YF, Chan HN (2011) Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre. Burns 37:1154\u20131160. https:\/\/doi.org\/10.1016\/j.burns.2011.07.006","journal-title":"Burns"},{"key":"905_CR105","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","volume":"20","author":"S He","year":"2022","unstructured":"He S, Gui J, Xiong K et al (2022) A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnol 20:101. https:\/\/doi.org\/10.1186\/s12951-022-01307-x","journal-title":"J Nanobiotechnol"},{"key":"905_CR106","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/tde-2017-0037","volume":"8","author":"SP Newman","year":"2017","unstructured":"Newman SP (2017) Drug delivery to the lungs: challenges and opportunities. Ther Deliv 8:647\u2013661","journal-title":"Ther Deliv"},{"key":"905_CR107","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40005-025-00729-7","volume":"55","author":"K Shah","year":"2025","unstructured":"Shah K, Anam R, Dormocara A et al (2025) Current trends in inhaled pharmaceuticals: challenges and opportunities in respiratory infections treatment. J Pharm Investig 55:191\u2013225. https:\/\/doi.org\/10.1007\/s40005-025-00729-7","journal-title":"J Pharm Investig"},{"key":"905_CR108","unstructured":"Jones D (2008) Fast Track - Pharmaceutics Dosage Form and Design. Pharmaceutical"},{"key":"905_CR109","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/jamp.2009.0745","volume":"23","author":"S Bai","year":"2010","unstructured":"Bai S, Gupta V, Ahsan F (2010) Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv 23:97\u2013104. https:\/\/doi.org\/10.1089\/jamp.2009.0745","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"905_CR110","doi-asserted-by":"crossref","unstructured":"Magramane S, Vlahovi K, Gordon P, Nikolett K (2023) Inhalation Dosage Forms. A Focus on Dry Powder Inhalers and Their Advancements","DOI":"10.3390\/ph16121658"},{"key":"905_CR111","doi-asserted-by":"publisher","unstructured":"Anaya BJ, Angelo DD, Bettini R et al (2025) Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections. 348. https:\/\/doi.org\/10.1016\/j.carbpol.2024.122930","DOI":"10.1016\/j.carbpol.2024.122930"},{"key":"905_CR112","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s11095-025-03883-7","volume":"42","author":"Z Liu","year":"2025","unstructured":"Liu Z, Ma Y, Shao Y et al (2025) Evaluation of the Combination of L \u2013 leucine to Chitosan on Sustained Release of Inhalable Heparin Sodium Microparticles. Pharm Res 42:1167\u20131180. https:\/\/doi.org\/10.1007\/s11095-025-03883-7","journal-title":"Pharm Res"},{"key":"905_CR113","doi-asserted-by":"publisher","first-page":"125802","DOI":"10.1016\/j.ijpharm.2025.125802","volume":"680","author":"Z Liu","year":"2025","unstructured":"Liu Z, Ye Y, Ma Y et al (2025) Development of high-dose carrier-free inhalable heparin sodium microparticles using co-jet-milling technology. Int J Pharm 680:125802. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125802","journal-title":"Int J Pharm"},{"key":"905_CR114","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2012.07.003","volume":"162","author":"B Patel","year":"2012","unstructured":"Patel B, Gupta V, Ahsan F (2012) PEG \u2013 PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Control Release 162:310\u2013320. https:\/\/doi.org\/10.1016\/j.jconrel.2012.07.003","journal-title":"J Control Release"},{"key":"905_CR115","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jconrel.2008.03.013","volume":"128","author":"A Rawat","year":"2008","unstructured":"Rawat A, Majumder QH, Ahsan F (2008) Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J Control Release 128:224\u2013232. https:\/\/doi.org\/10.1016\/j.jconrel.2008.03.013","journal-title":"J Control Release"},{"key":"905_CR116","doi-asserted-by":"crossref","unstructured":"Adania N, Nur S, Fatini D et al (2025) Inhaled biologics for respiratory diseases: clinical potential and emerging technologies. 4098\u20134114","DOI":"10.1007\/s13346-025-01909-6"},{"key":"905_CR117","doi-asserted-by":"publisher","unstructured":"Vincken W, Levy ML, Scullion J et al (2018) Spacer devices for inhaled therapy: why use them, and how? ERJ open Res 4. https:\/\/doi.org\/10.1183\/23120541.00065-2018","DOI":"10.1183\/23120541.00065-2018"},{"key":"905_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2022.2082307","volume":"0","author":"R Alsuwaigh","year":"2022","unstructured":"Alsuwaigh R, Cao Y, Puan Y et al (2022) Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era. J Asthma 0:1\u20139. https:\/\/doi.org\/10.1080\/02770903.2022.2082307","journal-title":"J Asthma"},{"key":"905_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","volume":"75","author":"C Sorino","year":"2020","unstructured":"Sorino C, Negri S, Spanevello A et al (2020) Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med 75:15\u201318. https:\/\/doi.org\/10.1016\/j.ejim.2020.02.023","journal-title":"Eur J Intern Med"},{"key":"905_CR120","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/17425247.2023.2231850","volume":"20","author":"V Komalla","year":"2023","unstructured":"Komalla V, Chun Yuen Jerry W, Imco S et al (2023) Advances in soft mist inhalers. Expert Opin Drug Deliv 20:1055\u20131070. https:\/\/doi.org\/10.1080\/17425247.2023.2231850","journal-title":"Expert Opin Drug Deliv"},{"key":"905_CR121","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/jamp.2008.0708","volume":"22","author":"PW Longest","year":"2009","unstructured":"Longest PW, Hindle M (2009) Evaluation of the Respimat Soft Mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv 22:99\u2013112","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"905_CR122","doi-asserted-by":"publisher","first-page":"575392","DOI":"10.2147\/DDDT.S575392","volume":"20","author":"S-C Wang","year":"2026","unstructured":"Wang S-C, Kuo T-H, Rai C-I, Chen Y-C (2026) Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery. Drug Des Devel Ther 20:575392. https:\/\/doi.org\/10.2147\/DDDT.S575392","journal-title":"Drug Des Devel Ther"},{"key":"905_CR123","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ajps.2015.07.004","volume":"10","author":"D Cipolla","year":"2015","unstructured":"Cipolla D, Gonda I (2015) Inhaled nicotine replacement therapy. Asian J Pharm Sci 10:472\u2013480. https:\/\/doi.org\/10.1016\/j.ajps.2015.07.004","journal-title":"Asian J Pharm Sci"},{"key":"905_CR124","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4155\/tde-2018-0071","volume":"10","author":"I Simpson","year":"2025","unstructured":"Simpson I (2025) Therapeutic delivery: Industry update covering October 2024. Ther Deliv 10:91\u201397. https:\/\/doi.org\/10.4155\/tde-2018-0071","journal-title":"Ther Deliv"},{"key":"905_CR125","doi-asserted-by":"crossref","unstructured":"Erelel M, Kaskal M, Akbal-dagistan O et al (2021) Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia. A Phase IIb Trial, pp 1\u201313","DOI":"10.3390\/pharmaceutics13111768"},{"key":"905_CR126","doi-asserted-by":"publisher","first-page":"114530","DOI":"10.1016\/j.ejpb.2024.114530","volume":"204","author":"K Berkenfeld","year":"2024","unstructured":"Berkenfeld K, Carneiro S, Corzo C et al (2024) Formulation strategies, preparation methods, and devices for pulmonary delivery of biologics. Eur J Pharm Biopharm 204:114530. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114530","journal-title":"Eur J Pharm Biopharm"},{"key":"905_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12080721","volume":"12","author":"KH Chang","year":"2020","unstructured":"Chang KH, Moon SH, Yoo SK et al (2020) Aerosol delivery of dornase alfa generated by jet and mesh nebulizers. Pharmaceutics 12:1\u201314. https:\/\/doi.org\/10.3390\/pharmaceutics12080721","journal-title":"Pharmaceutics"},{"key":"905_CR128","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jphp.12541","volume":"68","author":"TC Carvalho","year":"2016","unstructured":"Carvalho TC, McConville JT (2016) The function and performance of aqueous aerosol devices for inhalation therapy. J Pharm Pharmacol 68:556\u2013578. https:\/\/doi.org\/10.1111\/jphp.12541","journal-title":"J Pharm Pharmacol"},{"key":"905_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/ejp.2014.00087","volume":"16","author":"A Ari","year":"2014","unstructured":"Ari A (2014) Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. Eurasian J Pulmonol 16:1\u20137. https:\/\/doi.org\/10.5152\/ejp.2014.00087","journal-title":"Eurasian J Pulmonol"},{"key":"905_CR130","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5603\/ARM.2019.0029","volume":"87","author":"M Zieli\u0144ski","year":"2019","unstructured":"Zieli\u0144ski M, Wr\u00f3blewski P, Kozielski J (2019) Is inhaled heparin a viable therapeutic option in inhalation injury? Adv Respir Med 87:184\u2013188. https:\/\/doi.org\/10.5603\/ARM.2019.0029","journal-title":"Adv Respir Med"},{"key":"905_CR131","doi-asserted-by":"publisher","first-page":"e115938","DOI":"10.5812\/aapm.115938","volume":"11","author":"A Olapour","year":"2021","unstructured":"Olapour A, Rashidi M, Javaher Foroush F et al (2021) Effect of Nebulized Heparin on Weaning off Intubated Patients with Acute Respiratory Distress Syndrome (ARDS) Admitted to Intensive Care Unit (ICU): A Randomized Clinical Trial. Anesthesiol pain Med 11:e115938. https:\/\/doi.org\/10.5812\/aapm.115938","journal-title":"Anesthesiol pain Med"},{"key":"905_CR132","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4155\/tde-2021-0070","volume":"13","author":"SV Khairnar","year":"2022","unstructured":"Khairnar SV, Jain DD, Tambe SM et al (2022) Nebulizer Systems: A New Frontier for Therapeutics and Targeted Delivery. Ther Deliv 13:31\u201349. https:\/\/doi.org\/10.4155\/tde-2021-0070","journal-title":"Ther Deliv"},{"key":"905_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44446-025-00022-6","volume":"33","author":"M Albatsh","year":"2025","unstructured":"Albatsh M (2025) Emerging for non \u2013 invasive heparin delivery systems: recent advances, barriers, solutions, and applicability. Saudi Pharm J 33:1\u201317. https:\/\/doi.org\/10.1007\/s44446-025-00022-6","journal-title":"Saudi Pharm J"},{"key":"905_CR134","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijpharm.2013.02.035","volume":"447","author":"A Trapani","year":"2013","unstructured":"Trapani A, Di S, Ditaranto N et al (2013) Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles. Int J Pharm 447:115\u2013123. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.02.035","journal-title":"Int J Pharm"},{"key":"905_CR135","doi-asserted-by":"publisher","unstructured":"Fodor B, \u00c1lvarez-miguel I, Biglione C et al (2025) A Potential 3-in-1 Combined AntiSARS-CoV-2 Therapy Using Pulmonary MIL-100 (Fe) Formulation. 100:1\u201314. https:\/\/doi.org\/10.1002\/adhm.202403988","DOI":"10.1002\/adhm.202403988"},{"key":"905_CR136","doi-asserted-by":"publisher","unstructured":"Oyarzun-ampuero FA, Brea J, Loza MI et al (2009) Chitosan \u2013 hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. 381:122\u2013129. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.04.009","DOI":"10.1016\/j.ijpharm.2009.04.009"},{"key":"905_CR137","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/s0140-6736(76)91679-2","volume":"2","author":"LB Jaques","year":"1976","unstructured":"Jaques LB, Mahadoo J, Kavanagh LW (1976) Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet (London England) 2:1157\u20131161. https:\/\/doi.org\/10.1016\/s0140-6736(76)91679-2","journal-title":"Lancet (London England)"},{"key":"905_CR138","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1164\/ajrccm.160.5.9809123","volume":"160","author":"KE Bendstrup","year":"1999","unstructured":"Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT (1999) Lung deposition and clearance of inhaled 99mTc-heparin in healthy volunteers. Am J Respir Crit Care Med 160:1653\u20131658","journal-title":"Am J Respir Crit Care Med"},{"key":"905_CR139","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1183\/09031936.02.00105202","volume":"19","author":"KE Bendstrup","year":"2002","unstructured":"Bendstrup KE, Gram J, Jensen JI (2002) Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 19:606\u2013610. https:\/\/doi.org\/10.1183\/09031936.02.00105202","journal-title":"Eur Respir J"},{"key":"905_CR140","doi-asserted-by":"crossref","unstructured":"Iqbal Z, Sadaf S (2023) Commercial Low Molecular Weight Heparins \u2014 Patent Ecosystem and Technology Paradigm for Quality Characterization. Springer US","DOI":"10.1007\/s12247-022-09665-7"},{"key":"905_CR141","unstructured":"FDA (2013) Guidance for Industry - Heparin for Drug and Medical Device Use. Monitoring Crude Heparin for Quality"},{"key":"905_CR142","unstructured":"USP-NF (2024) Heparin and Heparin Sodium Monographs. Rockville, MD"},{"key":"905_CR143","volume-title":"European Directorate for the Quality of Medicines & HealthCare (EDQM)","author":"European Pharmacopoeia","year":"2025","unstructured":"European Pharmacopoeia (2025) European Directorate for the Quality of Medicines & HealthCare (EDQM), 12th edn. Strasbourg, France, France","edition":"12"},{"key":"905_CR144","unstructured":"Japanese Pharmacopoeia (2121) Ministry of Health, Labour and Welfare - Japanese Pharmacopoeia, 18th ed. Tokyo"},{"key":"905_CR145","doi-asserted-by":"crossref","unstructured":"Devlin A, Mycroft-west C, Procter P et al (2019) Tools for the Quality Control of Pharmaceutical Heparin. 1\u201319","DOI":"10.3390\/medicina55100636"},{"key":"905_CR146","unstructured":"View G (2026) Heparin Market (2024\u20132030). https:\/\/www.grandviewresearch.com\/industry-analysis\/heparin-market. Accessed 29 Jan 2026"},{"key":"905_CR147","first-page":"100493","volume":"7","author":"S Zare","year":"2024","unstructured":"Zare S, Eskandani M, Vandghanooni S et al (2024) Ciprofloxacin-loaded chitosan-based nanocomposite hydrogel containing silica nanoparticles as a scaffold for bone tissue engineering application. Carbohydr Polym Technol Appl 7:100493","journal-title":"Carbohydr Polym Technol Appl"},{"key":"905_CR148","unstructured":"Therapeutics H (2026) Heparin Therapeutics. https:\/\/www.heparintherapeutics.com\/. Accessed 2 Apr 2026"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00905-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00905-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00905-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:11Z","timestamp":1791061331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00905-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":148,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00905-y","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"44"}}